Cadonilimab and nab-paclitaxel for advanced stomach cancer after PD-1 therapy
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs, cadonilimab and a type of paclitaxel, for people with advanced stomach or gastroesophageal junction cancer that has stopped responding to prior immunotherapy (PD-1/PD-L1 inhibitors). The goal is to see if this new combination can help shrink tumors or slow disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread.
- Your cancer has gotten worse or you could not tolerate previous treatment that included a PD-1 or PD-L1 inhibitor (a type of immunotherapy).
- You must have at least one measurable tumor (by scan) and be willing to provide a recent or stored tumor tissue sample.
- Your overall health (ECOG score) should be 0 or 1, meaning you are fully active or only limited in strenuous activity.
- You must not have had prior treatment with taxane drugs like paclitaxel or docetaxel.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy for people with advanced stomach cancer that hasn't been treated yet. It compares this combination to chemotherapy with or without another immunotherapy drug, nivolumab.
This trial tests a combination of two experimental immunotherapies (AK104 and AK109) with a standard chemo drug (paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has grown after initial treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer better than chemo alone.
This trial tests a combination of two drugs, nab-paclitaxel and cadonilimab, as a second treatment for advanced stomach cancer that has spread to the belly lining. It may be an option if you haven't had any prior cancer therapy.
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy before surgery for stomach or gastroesophageal junction cancer. The goal is to shrink the tumor and improve outcomes for patients who are candidates for surgery.
This trial tests a combination of three drugs—cadonilimab, fruquintinib, and albumin-bound paclitaxel—as a second treatment for advanced stomach cancer. It may be an option if your first treatment stopped working and you have not had certain types of prior therapy.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.